Rick E. Winningham - 15 May 2024 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
15 May 2024
Net transactions value
+$20,370
Form type
4
Filing time
17 May 2024, 18:01:45 UTC
Previous filing
04 Apr 2024
Next filing
22 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $20,370 +2,068 +0.11% $9.85 1,852,641 15 May 2024 Direct F1
holding TBPH Ordinary Shares 3,900 15 May 2024 As Custodian
holding TBPH Ordinary Shares 92,567 15 May 2024 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on May 15, 2024. Transaction was with the Issuer and did not involve an open market transaction.